Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Saralasin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 3/20 | 0.55 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.53 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.53 |
| ▸ | APLNR | P35414 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSH | P09668 | 1/20 | 0.51 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.48 |
| ▸ | CALCR | P30988 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saralasin SCHEMBL23 | 0.99 | C5AR1 (0.59) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Saralasin SCHEMBL18699973 | 0.99 | C5AR1 (0.59) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Saralasin SCHEMBL2200145 | 0.99 | C5AR1 (0.57) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Saralasin SCHEMBL125013 | 0.98 | C5AR1 (0.58) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| SCHEMBL19780882 | 0.98 | C5AR1 (0.60) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| SCHEMBL34470047 | 0.97 | C5AR1 (0.62) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Trv-120027 SCHEMBL19780884 | 0.96 | AGTR1 (0.60) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Trv-120027 SCHEMBL17274209 | 0.96 | AGTR1 (0.60) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Trv-120027 SCHEMBL17274208 | 0.96 | AGTR1 (0.60) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Trv-120027 SCHEMBL11024001 | 0.96 | AGTR1 (0.60) | C5AR1AGTR1EPHA2AGTR2APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | AGTR1 1066/4885C5AR1 402/4885EPHA2 459/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | AGTR1 3279/4885C5AR1 2276/4885EPHA2 1034/4885 |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | AGTR1 1066/4885C5AR1 402/4885EPHA2 459/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | AGTR1 1066/4885C5AR1 402/4885EPHA2 459/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | AGTR1 1130/4885C5AR1 191/4885EPHA2 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.